Innovative Medicine
-
-
-
Janssen Announces Submissions in Europe and US for Single- Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment
- Two-drug regimen could offer many patients the option to switch to a regimen that does not include a nucleotide reverse transcriptase inhibitor - -
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. For The Oral Interlukin-23 Receptor Antagonist Drug Candidate For The Treatment of Inflammatory Bowel Disease
Long-standing relationship between Johnson & Johnson Innovation, Janssen and Protagonist Therapeutics leads to advancement of promising oral drug candidate for Crohn’s disease and ulcerative colitis -
-
Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists
Patients Taking INVOKANA® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent -
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups
Filing seeks update to prescribing information to include additional dosage of XARELTO® to reduce risk of recurrent VTE -
European Commission Extends Approval for Janssen’s DARZALEX®▼(daratumumab) to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy
First-in-class CD38-directed monoclonal antibody now approved for use in combination with two standard of care regimens -